A new trading day began on Tuesday, with Akero Therapeutics Inc (NASDAQ: AKRO) stock price down -6.46% from the previous day of trading, before settling in for the closing price of $44.92. AKRO’s price has ranged from $17.86 to $58.40 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged -12.20%. With a float of $70.76 million, this company’s outstanding shares have now reached $72.38 million.
Let’s determine the extent of company efficiency that accounts for 63 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Akero Therapeutics Inc (AKRO) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Akero Therapeutics Inc is 11.19%, while institutional ownership is 88.05%. The most recent insider transaction that took place on May 06 ’25, was worth 2,000,000. Before that another transaction happened on Apr 24 ’25, when Company’s Chief Scientific Officer sold 6,250 for $41.03, making the entire transaction worth $256,438. This insider now owns 169,721 shares in total.
Akero Therapeutics Inc (AKRO) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -12.20% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -8.19% during the next five years compared to -5.28% drop over the previous five years of trading.
Akero Therapeutics Inc (NASDAQ: AKRO) Trading Performance Indicators
Here are Akero Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 19.38.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.75, a number that is poised to hit -0.96 in the next quarter and is forecasted to reach -4.61 in one year’s time.
Technical Analysis of Akero Therapeutics Inc (AKRO)
Looking closely at Akero Therapeutics Inc (NASDAQ: AKRO), its last 5-days average volume was 1.21 million, which is a drop from its year-to-date volume of 1.34 million. As of the previous 9 days, the stock’s Stochastic %D was 66.92%. Additionally, its Average True Range was 2.43.
During the past 100 days, Akero Therapeutics Inc’s (AKRO) raw stochastic average was set at 55.80%, which indicates a significant increase from 55.54% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 44.77% in the past 14 days, which was lower than the 122.12% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $42.17, while its 200-day Moving Average is $34.12. However, in the short run, Akero Therapeutics Inc’s stock first resistance to watch stands at $43.84. Second resistance stands at $45.65. The third major resistance level sits at $46.69. If the price goes on to break the first support level at $40.99, it is likely to go to the next support level at $39.95. Should the price break the second support level, the third support level stands at $38.14.
Akero Therapeutics Inc (NASDAQ: AKRO) Key Stats
With a market capitalization of 3.35 billion, the company has a total of 79,679K Shares Outstanding. Currently, annual sales are 0 K while annual income is -252,060 K. The company’s previous quarter sales were 0 K while its latest quarter income was -70,020 K.
